Literature DB >> 33620671

Small-sized extracellular vesicles (EVs) derived from acute myeloid leukemia bone marrow mesenchymal stem cells transfer miR-26a-5p to promote acute myeloid leukemia cell proliferation, migration, and invasion.

Dexiang Ji1, Yue He1, Wei Lu1, Yanyan Rong1, Fei Li1, Xianbao Huang1, Ruibin Huang1, Yanxia Jiang2, Guoan Chen3.   

Abstract

Bone marrow mesenchymal stem cells (BMSCs) in acute myeloid leukemia (AML) microenvironment undergo modification that includes expression of contents in the small-sized extracellular vesicles (EVs) they secrete. This study aims to investigate whether small-sized EVs from BMSCs of AML patients regulate AML progression by modifying the expression of miR-26a-5p. Small-sized EVs from BMSCs of AML patients (AML-BMSC-EVs) or healthy controls (HC-BMSC-EVs) were isolated by ultra-centrifugation and administered to AML cells (OCI/AML-2 and THP-1). Cell proliferation, migration, and invasion were evaluated by CCK-8 assay, Transwell migration and invasion assays, respectively. Compared with HC-BMSC-EVs, AML-BMSC-EVs contained higher expression of miR-26a-5p and promoted AML cell proliferation, migration, and invasion. Inhibition of miR-26a-5p expression in AML-BMSC-EVs could abrogate the promoting effects of AML-BMSC-EVs on AML cell proliferation, migration, and invasion. Furthermore, GSK3β was a direct target of miR-26a-5p. Moreover, AML-BMSC-EVs inhibited GSK3β expression and activated Wnt/β-catenin signaling in AML cells. Additionally, GSK3β overexpression in THP-1 cells counteracted the promoting effects of AML-BMSCs-EVs on THP-1 cell proliferation, migration, and invasion. AML-BMSC-EVs promoted AML progression by transferring miR-26a-5p to AML cells and subsequently activating the Wnt/β-catenin pathway.

Entities:  

Keywords:  Acute myeloid leukemia; GSK3β; Mesenchymal stem cells; Small-sized EVs; miR-26a-5p

Year:  2021        PMID: 33620671     DOI: 10.1007/s13577-021-00501-7

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  14 in total

Review 1.  Hematopoietic Support Capacity of Mesenchymal Stem Cells: Biology and Clinical Potential.

Authors:  Guadalupe R Fajardo-Orduña; Héctor Mayani; Juan J Montesinos
Journal:  Arch Med Res       Date:  2015-10-29       Impact factor: 2.235

Review 2.  Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities.

Authors:  Jacques Galipeau; Luc Sensébé
Journal:  Cell Stem Cell       Date:  2018-06-01       Impact factor: 24.633

Review 3.  Modulatory effects of mesenchymal stem cells on leucocytes and leukemic cells: A double-edged sword?

Authors:  Jun How Low; Premdass Ramdas; Ammu Kutty Radhakrishnan
Journal:  Blood Cells Mol Dis       Date:  2015-08-01       Impact factor: 3.039

Review 4.  Exosome-mediated cell-cell communication in tumor progression.

Authors:  Zhuo Wan; Xiaotong Gao; Yan Dong; Yingxin Zhao; Xutao Chen; Guodong Yang; Li Liu
Journal:  Am J Cancer Res       Date:  2018-09-01       Impact factor: 6.166

5.  Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance.

Authors:  Shelton Viola; Elie Traer; Jianya Huan; Noah I Hornick; Jeffrey W Tyner; Anupriya Agarwal; Marc Loriaux; Brian Johnstone; Peter Kurre
Journal:  Br J Haematol       Date:  2015-06-11       Impact factor: 6.998

Review 6.  Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia.

Authors:  Felicetto Ferrara; Salvatore Palmieri; Giuseppina Mele
Journal:  Haematologica       Date:  2004-08       Impact factor: 9.941

7.  BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

Authors:  Aldo M Roccaro; Antonio Sacco; Patricia Maiso; Abdel Kareem Azab; Yu-Tzu Tai; Michaela Reagan; Feda Azab; Ludmila M Flores; Federico Campigotto; Edie Weller; Kenneth C Anderson; David T Scadden; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

8.  Mouse bone marrow-derived mesenchymal stem cells inhibit leukemia/lymphoma cell proliferation in vitro and in a mouse model of allogeneic bone marrow transplant.

Authors:  Ningxia Song; Lei Gao; Huiying Qiu; Chongmei Huang; Hui Cheng; Hong Zhou; Shuqing Lv; Li Chen; Jianmin Wang
Journal:  Int J Mol Med       Date:  2015-04-21       Impact factor: 4.101

9.  Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection.

Authors:  Rui Cui; Cuicui Lyu; Qing Li; Yanyu Jiang; Nan Mou; Zhenxing Yang; Xuxiang Liu; Qi Deng; Lanfang Li
Journal:  Hematol Oncol       Date:  2020-09-19       Impact factor: 5.271

Review 10.  'Acute myeloid leukemia: a comprehensive review and 2016 update'.

Authors:  I De Kouchkovsky; M Abdul-Hay
Journal:  Blood Cancer J       Date:  2016-07-01       Impact factor: 11.037

View more
  3 in total

Review 1.  Extracellular Vesicles in Haematological Disorders: A Friend or a Foe?

Authors:  Ioanna Lazana
Journal:  Int J Mol Sci       Date:  2022-09-04       Impact factor: 6.208

Review 2.  Mesenchymal stem cell-derived exosomes as new tools for delivery of miRNAs in the treatment of cancer.

Authors:  Aysegul Dalmizrak; Ozlem Dalmizrak
Journal:  Front Bioeng Biotechnol       Date:  2022-09-26

3.  Scalable Enrichment of Immunomodulatory Human Acute Myeloid Leukemia Cell Line-Derived Extracellular Vesicles.

Authors:  Heide-Marie Binder; Nicole Maeding; Martin Wolf; André Cronemberger Andrade; Balazs Vari; Linda Krisch; Fausto Gueths Gomes; Constantin Blöchl; Katharina Muigg; Rodolphe Poupardin; Anna M Raninger; Thomas Heuser; Astrid Obermayer; Patricia Ebner-Peking; Lisa Pleyer; Richard Greil; Christian G Huber; Katharina Schallmoser; Dirk Strunk
Journal:  Cells       Date:  2021-11-26       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.